“It does prevent that thing where people start to get drunk and the music is loud and they start screaming into each other’s face, which is the way that the COVID-19 is most spread. … Not screaming bad, but that’s just how conversations are when you’re at big gatherings,” Wayne Coyne said. “You can be in a Space Bubble with your friends that came to the show with you who you’ve been with your whole time and you know aren’t sick.”
A report from two CDC scientists was published online today in JAMA Insights which describes in detail 21 cases of anaphylaxis that were reported to the US Vaccine Adverse Events Reporting System between December 14-23, 2020. This corresponds to a very low rate of 11.1 cases of anaphylaxis per million doses administered. 17 of these…
I continue to urge all my patients to get vaccinated as soon as possible. Benefits far outweigh the risk.
Labs and blood banks collect millions of blood samples each month, offering a distinctive source of data on the disease…
Their data so far suggest that a lot of people have had Covid-19 without ever receiving a diagnosis. Confirmed case counts suggest that almost 7 percent of people in the U.S. have had the virus. Data from the arm of the study looking at blood from clinical laboratory tests from all 50 states, the District of Columbia, and Puerto Rico found rates of antibody positivity that at times ranged from under 1 percent in some states to 23 percent in New York…
Some experts have reservations about the use of blood donation data to estimate the prevalence of Covid-19. “The problem with blood donors — and this is also supported by evidence from other epidemics like HIV, and previous pandemics — is that blood donors are weird people” from a statistical point of view, said Gideon Meyerowitz-Katz, an epidemiologist at the University of Wollongong. “And blood donors who give blood during a pandemic, when the country is in lockdown in particular, are very weird people.”
In a study published in the Journal of Neuroimmune Pharmacology, mouse models with COVID-19 showed positive results when a small peptide was introduced nasally. The peptide proved effective in reducing fever, protecting the lungs, improving heart function and reversing cytokine storm — a condition in which an infection triggers the immune system to flood the bloodstream with inflammatory proteins. The researchers also report success in preventing the disease from progression.
Journal Reference – Ramesh K. Paidi, Malabendu Jana, Rama K. Mishra, Debashis Dutta, Sumita Raha, Kalipada Pahan. ACE-2-interacting Domain of SARS-CoV-2 (AIDS) Peptide Suppresses Inflammation to Reduce Fever and Protect Lungs and Heart in Mice: Implications for COVID-19 Therapy. Journal of Neuroimmune Pharmacology, 2021; DOI: 10.1007/s11481-020-09979-8
Our neighbor Dr. Arlan Richardson at https://nathanshockcenters.org/oklahoma part of the University of Oklahoma Health Sciences Center knows a lot about mice. I’ll have to ask him what he thinks of the potential of this peptide for human use.
In 2014, I finished an MA thesis at the University of Chicago. In that thesis, I argued that as economic inequality increased, American politics would return to the sharp political divisions of the 1930s, with both left-wing and right-wing radical movements popping up all over the place. Recently, I finished a PhD thesis at the […]
By Jesse Lee Kercheval Outside there is a pandemic and I am in lockdown in Montevideo, Uruguay, far from my daughter and son also locked down, but in Kanazawa, in Ishikawa Prefecture, Japan, and I am inside drawing, drawing, drawing, filling sheets of paper, pages drifting to the floor, as if I were the boy […]
In a review published this week in mBio, microbiologist Heenam Stanley Kim, Ph.D, from Korea University’s Laboratory for Human-Microbial Interactions, in Seoul, examined emerging evidence suggesting that poor gut health adversely affects COVID-19 prognosis. Based on his analysis, Kim proposed that gut dysfunction — and its associated leaky gut — may exacerbate the severity of infection by enabling the virus to access the surface of the digestive tract and internal organs. These organs are vulnerable to infection because they have widespread ACE2 — a protein target of SARS-CoV-2 — on the surface.”There seems to be a clear connection between the altered gut microbiome and severe COVID-19,” Kim said.
A total of 800 adults aged 18 to 55 or aged 65 and up were randomized to various combinations of low-dose or high-dose vaccines or placebo, given 56 days apart.
Adverse events were common, with fatigue, headache, myalgia, and injection-site pain reported most often. At day 29 after the first dose, the seroconversion rate was 99% or more in the younger cohort across dosing groups. Older vaccine recipients had a 96% seroconversion rate. At 57 days after the first dose, antibody titers had increased further.
There are two Phase 3 studies running. A 40,000-volunteer study of the one-dose vaccine, conducted in the U.S., is set to read out in the next two weeks. A second, equally big study is being conducted using the same vaccine given as two doses, each administered 57 days apart, in case the vaccine does not prove effective in a one-dose regimen or there are other advantages, such as the durability of the vaccine, to giving a second dose.
Unlike the Pfizer/BioNTech and Moderna messenger RNA vaccines, the Johnson & Johnson product is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike (S) protein.